WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc (BMRN) said Monday the
European Commission has granted marketing authorization for Vimizim, the first
specific treatment approved in the European Union for Mucopolysaccharidosis type
IVA (MPS IVA;...
CES (Booth #9839) —DTS,
Inc. (Nasdaq:DTSI), a leader in high-definition audio solutions and
audio enhancement technologies, announced today that it has teamed up
Video Archive (IVA), the world’s...
Inc. (Nasdaq: BMRN) today announced that the Endocrinologic and Metabolic Drugs
Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA)
voted in favor of approval of Vimizim for the treatment of Morquio A...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that NASDAQ has halted trading of the company's stock. The U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) is meeting today to...
CodeBaby, a leading intelligent virtual assistant (IVA) technology provider for the benefits health insurance and provider industries, today announced that it has contracted with CareFirst BlueCross BlueShield (CareFirst), the largest health...
Largest Phase 3 ERT Study to Date in a Lysosomal Storage Disease Results Expected in the Fourth Quarter of 2012 NOVATO, Calif., March 8, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that enrollment is complete
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.